These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34610580)

  • 1. Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes mellitus patients than paroxetine/fluoxetine.
    Liang Z; Jia Y; Zhao L; Zhu R; He X; Tong B; Yang F; Hao L; Cui P; Yuan J
    Aging (Albany NY); 2021 Oct; 13(19):22934-22946. PubMed ID: 34610580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agomelatine versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: a single-blind randomized controlled trial.
    Che T; Teng X; Huang Q; Mu Y; Tang X; Mu X; Wei Y
    Neuropsychiatr Dis Treat; 2018; 14():1527-1533. PubMed ID: 29942131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
    Demyttenaere K; Corruble E; Hale A; Quera-Salva MA; Picarel-Blanchot F; Kasper S
    CNS Spectr; 2013 Jun; 18(3):163-70. PubMed ID: 23472671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial.
    Kang R; He Y; Yan Y; Li Z; Wu Y; Guo X; Liang Z; Jiang J
    Neuropsychiatr Dis Treat; 2015; 11():1307-11. PubMed ID: 26064049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients.
    Gülseren L; Gülseren S; Hekimsoy Z; Mete L
    Arch Med Res; 2005; 36(2):159-65. PubMed ID: 15847950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agomelatine: new drug. Adverse effects and no proven efficacy.
    Prescrire Int; 2009 Dec; 18(104):241-5. PubMed ID: 20020562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Agomelatine and Fluoxetine on HAM-D Score, Serum Brain-Derived Neurotrophic Factor, and Tumor Necrosis Factor-α Level in Patients With Major Depressive Disorder With Severe Depression.
    Gupta K; Gupta R; Bhatia MS; Tripathi AK; Gupta LK
    J Clin Pharmacol; 2017 Dec; 57(12):1519-1526. PubMed ID: 28833192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA).
    Yeh TC; Kao LC; Tzeng NS; Kuo TB; Huang SY; Chang CC; Chang HA
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():60-7. PubMed ID: 26216863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.
    Shu L; Sulaiman AH; Huang YS; Fones Soon Leng C; Crutel VS; Kim YS
    Asian J Psychiatr; 2014 Apr; 8():26-32. PubMed ID: 24655622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease.
    Chen JW; Xie SQ
    Neuropsychiatr Dis Treat; 2018; 14():547-552. PubMed ID: 29497298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
    Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
    Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.
    Montgomery SA; Kennedy SH; Burrows GD; Lejoyeux M; Hindmarch I
    Int Clin Psychopharmacol; 2004 Sep; 19(5):271-80. PubMed ID: 15289700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.
    Lôo H; Hale A; D'haenen H
    Int Clin Psychopharmacol; 2002 Sep; 17(5):239-47. PubMed ID: 12177586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial.
    Paile-Hyvärinen M; Wahlbeck K; Eriksson JG
    BMC Fam Pract; 2007 Jun; 8():34. PubMed ID: 17570858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.
    Montejo AL; Prieto N; Terleira A; Matias J; Alonso S; Paniagua G; Naval S; Parra DG; Gabriel C; Mocaër E; Portolés A
    J Psychopharmacol; 2010 Jan; 24(1):111-20. PubMed ID: 18801825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depressive symptoms, monoamines levels, MAO-B activity and effect of treatment in a subset of depressed individuals from government sector hospital at Karachi.
    Zeb F; Naqvi S; Rahman R; Farooq AD
    Pak J Pharm Sci; 2017 Jul; 30(4(Suppl.)):1509-1519. PubMed ID: 29044007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects.
    Geretsegger C; Böhmer F; Ludwig M
    Int Clin Psychopharmacol; 1994; 9(1):25-9. PubMed ID: 8195578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.
    Versiani M; Moreno R; Ramakers-van Moorsel CJ; Schutte AJ;
    CNS Drugs; 2005; 19(2):137-46. PubMed ID: 15697327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.
    Stein DJ; Ahokas A; Albarran C; Olivier V; Allgulander C
    J Clin Psychiatry; 2012 Jul; 73(7):1002-8. PubMed ID: 22901350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of agomelatine on sexual function in depressed patients and healthy volunteers.
    Montejo A; Majadas S; Rizvi SJ; Kennedy SH
    Hum Psychopharmacol; 2011 Dec; 26(8):537-42. PubMed ID: 22102540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.